# Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence

> **NCT05205746** · PHASE2 · COMPLETED · sponsor: **Laboratorio Avi-Mex, S.A. de C.V.** · enrollment: 158 (actual)

## Conditions studied

- SARS CoV 2 Infection

## Interventions

- **BIOLOGICAL:** Recombinant NDV Vectored Vaccine for SARS-CoV-2
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05205746
- **Lead sponsor:** Laboratorio Avi-Mex, S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-23
- **Primary completion:** 2022-08-09
- **Final completion:** 2023-07-24
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05205746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05205746, "Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05205746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*